Pretax income is the income that a company earns before paying income taxes. Sutro Biopharma's pretax income for the
three
months ended in Mar. 2024 was $-58.2 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-97.2 Mil.
Sutro Biopharma's pretax margin was -447.52%.
During the past 8 years, Sutro Biopharma's highest Pretax Margin was 2.85%. The lowest was -172.20%. And the median was -83.45%.
Sutro Biopharma Pre-Tax Income Historical Data
The historical data trend for Sutro Biopharma's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sutro Biopharma's Pre-Tax Income
For the Biotechnology subindustry, Sutro Biopharma's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sutro Biopharma's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sutro Biopharma's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Sutro Biopharma's Pre-Tax Income falls into.
Sutro Biopharma Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Sutro Biopharma's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-97.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sutro Biopharma (NAS:STRO) Pre-Tax Income Explanation
Sutro Biopharma's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
During the past 8 years, Sutro Biopharma's highest Pretax Margin was 2.85%. The lowest was -172.20%. And the median was -83.45%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sutro Biopharma Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Sutro Biopharma's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Sutro Biopharma (Sutro Biopharma) Business Description
Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STRO has been successfully added to your 